Search Results - "Samalin, E"

Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature by de la Fouchardiere, C., Decoster, L., Samalin, E., Terret, C., Kenis, C., Droz, J.P., Coutzac, C., Smyth, E.

“…•Older patients (≥70 years) represent more than half of the oesogastric cancer (OGC) incidental population.•They are largely under-represented in clinical…”
Get full text

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS) by Adenis, A., Bennouna, J., Etienne, P.L., Bogart, E., Francois, E., Galais, M.P., Ben Abdelghani, M., Michel, P., Metges, J.P., Dahan, L., Conroy, T., Ghiringhelli, F., Drouillard, A., El Hajbi, F., Samalin, E., Hiret, S., Delaine-Clisant, S., Mariette, C., Penel, N., Piessen, G., Le Deley, M.C.

“…The role of chemotherapy has not been established in the treatment of metastatic squamous cell oesophageal cancer (mESCC). E-DIS is a discontinuation trial,…”
Get full text

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial by Touchefeu, Y., Guimbaud, R., Louvet, C., Dahan, L., Samalin, E., Barbier, E., Le Malicot, K., Cohen, R., Gornet, J. M., Aparicio, T., Nguyen, S., Azzedine, A., Etienne, P. L., Phelip, J. M., Hammel, P., Chapelle, N., Sefrioui, D., Mineur, L., Lepage, C., Bouche, O.

“…Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and…”
Get full text

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial by Samalin, E, Bouché, O, Thézenas, S, Francois, E, Adenis, A, Bennouna, J, Taieb, J, Desseigne, F, Seitz, J F, Conroy, T, Galais, M P, Assenat, E, Crapez, E, Poujol, S, Bibeau, F, Boissière, F, Laurent-Puig, P, Ychou, M, Mazard, T

“…Background: This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with…”
Get full text

Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients by Samalin, E., Mazard, T., Assenat, E., Rouyer, M., De la Fouchardière, C., Guimbaud, R., Smith, D., Portales, F., Ychou, M., Fiess, C., de Forges, H., Lopez-Crapez, E., Thézenas, S.

Get full text

Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI) by Samalin, E., Turpin, A., Khemissa, F., Zaanan, A., Benabdelghani, M., Senellart, H., Gilabert, M., Evesque, L., Dahan, L., Sefrioui, D., Bouché, O., De la Fouchardière, C., Hennequin, A., Monard, L., Gourgou, S., Lopez, A.

Get full text

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202) by Rao, S., Anandappa, G., Capdevila, J., Dahan, L., Evesque, L., Kim, S., Saunders, M.P., Gilbert, D.C., Jensen, L.H., Samalin, E., Spindler, K.-L., Tamberi, S., Demols, A., Guren, M.G., Arnold, D., Fakih, M., Kayyal, T., Cornfeld, M., Tian, C., Catlett, M., Smith, M., Spano, J.-P.

“…Locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) has poor prognosis following platinum-based chemotherapy. Retifanlimab…”
Get full text

HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma by Bernard-Tessier, A., Jeannot, E., Guenat, D., Michel, M., Proudhon, C., Vincent-Salomon, A., Bièche, I., Pierga, J.-Y., Buecher, B., Francois, E., Kim, S., André, T., Jary, M., Vendrely, V., Samalin, E., El Hajbi, F., Baba-Hamed, N., Meurisse, A., Bidard, F.-C., Borg, C.

Get full text

LBA-04The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results by Bennouna, J., Etienne, P.-L., Bogart, E., Galais, M.-P., Benabdelghani, M., Francois, E., Michel, P., Dahan, L., Metges, J.-P., Ghiringhelli, F., Conroy, T., Kotecki, N., Bedenne, L., El Hajbi, F., Samalin, E., Piessen, G., Delaine-Clisant, S., Penel, N., Mariette, C., Adenis, A.

Get full text

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm by Reguiai, Z., Bachet, J. B., Bachmeyer, C., Peuvrel, L., Beylot-Barry, M., Bezier, M., Boucher, E., Chevelle, C., Colin, P., Guimbaud, R., Mineur, L., Richard, M. A., Artru, P., Dufour, P., Gornet, J. M., Samalin, E., Bensadoun, R. J., Ychou, M., André, T., Dreno, B., Bouché, O.

“…Purpose Cutaneous adverse events induced by epidermal growth factor receptor (EGFR) inhibitors can hamper the patients' quality of life. The aim of our work…”
Get full text

Two-stage hepatectomy for colorectal metastases: A good histo-pathologic response to intensified preoperative chemotherapy is associated with second-stage completion and longer survival by Pissas, M.-H, Bibeau, F, Gil, H, Roca, L, Lemoyne-de-Forges, H, Samalin, E, Carrere, S, Rouanet, P, Saint Aubert, B, Ychou, M, Quenet, F

Get full text

Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX by Mazard, T., Ychou, M., Thezenas, S., Poujol, S., Pinguet, F., Thirion, A., Bleuse, J. P., Portales, F., Samalin, E., Assenat, E.

“…Background Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in…”
Get full text

Self-expandable metal stents placed with overtube for the treatment of malignant obstruction of the gastrointestinal tract in 33 consecutive patients by Samalin, E, Assenat, E, Bauret, P, Senesse, P

Get more information

6091 POSTER Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI) by Samalin, E, Bouche, O, Thezenas, S, Frangois, E, Adenis, A, Bennouna, J, Taieb, J, Desseigne, F, Laurent-Puig, P, Ychou, M

Get full text

The value of endoscopic rectal ultrasound in predicting the lateral clearance and outcome in patients with lower-third rectal adenocarcinoma by Assenat, E, Thézenas, S, Samalin, E, Bibeau, F, Portales, F, Azria, D, Quenet, F, Rouanet, P, Saint Aubert, B, Senesse, P

“…The aim of this study was to assess whether preoperative endorectal ultrasound (ERUS) is able to predict histological infiltration of the external anal…”
Get more information

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment by Samalin, E, Afchain, P, Thézenas, S, Abbas, F, Romano, O, Guimbaud, R, Bécouarn, Y, Desseigne, F, Edeline, J, Mitry, E, Bouché, O, Adenis, A, Aparicio, T, Dorval, E, Kramar, A, Ychou, M

“…Summary Objectives The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA…”
Get full text

P-102 Unmet needs of patients during colorectal cancer care and treatment – a qualitative study through an online patient community by Samalin, E., Lorenzon, L., Sarrauste de Menthière, C., Guéroult-Accolas, L., Paixão, R., Almagro, C. Chaves, Pain, E., Martinelli, E.

Get full text

555P - Impact of the IDEA study on clinical practice for stage III colon cancer patients: A French GERCOR - FFCD - GI UNICANCER national survey by Ouali, K., Cohen, R., Turpin, A., Neuzillet, C., Rousseau, B., Garcia-Larnicol, M.-L., Tournigand, C., Samalin, E., Taieb, J., André, T.

“…The IDEA study showed that the type and duration of adjuvant chemotherapy in stage III colon cancer (CC) could be adjusted according to level of risk (Grothey…”
Get full text

555PImpact of the IDEA study on clinical practice for stage III colon cancer patients: A French GERCOR - FFCD - GI UNICANCER national survey by Ouali, K, Cohen, R, Turpin, A, Neuzillet, C, Rousseau, B, Garcia-Larnicol, M-L, Tournigand, C, Samalin, E, Taieb, J, André, T

“…Abstract Background The IDEA study showed that the type and duration of adjuvant chemotherapy in stage III colon cancer (CC) could be adjusted according to…”
Get full text

Impact of the IDEA study on clinical practice for stage III colon cancer patients: A French GERCOR - FFCD - GI UNICANCER national survey by Ouali, K., Cohen, R., Turpin, A., Neuzillet, C., Rousseau, B., Garcia-Larnicol, M.-L., Tournigand, C., Samalin, E., Taieb, J., André, T.

Get full text